Javascript must be enabled to continue!
GABA Transporters GAT-1 and GAT-3 in the Human Dorsolateral Prefrontal Cortex in Schizophrenia
View through CrossRef
This study aimed to investigate the binding affinity of [<sup>3</sup>H]GABA and [<sup>3</sup>H]β-alanine to GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex (Brodmanns’ area 9) in schizophrenia. Using post mortem tissue from individuals diagnosed with schizophrenia (n = 6) and control subjects (n = 6), the density of GAT-1 was established by displacing [<sup>3</sup>H]GABA with muscimol, and for GAT-3 [<sup>3</sup>H]β-alanine was used. Data analysis showed a significant decrease of GAT-1 levels (45%), and a significant increase of GAT-3 density (23%) within the dorsolateral prefrontal cortex of individuals diagnosed with schizophrenia when compared to age- and sex-matched controls. The observed decrease of GAT-1 could be explained as a consequence of the GABA hypo-function or the result of volumetric shrinkage of the cerebral cortex previously reported in this disease. The observed elevation of GAT-3 levels could be due to a compensatory effect for any functional loss of GABA re-uptake by the decreased GAT-1 levels.
Title: GABA Transporters GAT-1 and GAT-3 in the Human Dorsolateral Prefrontal Cortex in Schizophrenia
Description:
This study aimed to investigate the binding affinity of [<sup>3</sup>H]GABA and [<sup>3</sup>H]β-alanine to GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex (Brodmanns’ area 9) in schizophrenia.
Using post mortem tissue from individuals diagnosed with schizophrenia (n = 6) and control subjects (n = 6), the density of GAT-1 was established by displacing [<sup>3</sup>H]GABA with muscimol, and for GAT-3 [<sup>3</sup>H]β-alanine was used.
Data analysis showed a significant decrease of GAT-1 levels (45%), and a significant increase of GAT-3 density (23%) within the dorsolateral prefrontal cortex of individuals diagnosed with schizophrenia when compared to age- and sex-matched controls.
The observed decrease of GAT-1 could be explained as a consequence of the GABA hypo-function or the result of volumetric shrinkage of the cerebral cortex previously reported in this disease.
The observed elevation of GAT-3 levels could be due to a compensatory effect for any functional loss of GABA re-uptake by the decreased GAT-1 levels.
Related Results
Modelling the spatial and temporal constrains of the GABAergic influence on neuronal excitability
Modelling the spatial and temporal constrains of the GABAergic influence on neuronal excitability
Abstract
GABA (γ-amino butyric acid) is an inhibitory neurotransmitter in the adult brain that can mediate depolarizing responses during developm...
Immune response to the p-azobenzenearsonate (ABA)-GAT conjugate. II. Hapten-specific T cells induced with ABA-GAT in GAT responder X nonresponder F1 hybrids are restricted to the nonresponder haplotype.
Immune response to the p-azobenzenearsonate (ABA)-GAT conjugate. II. Hapten-specific T cells induced with ABA-GAT in GAT responder X nonresponder F1 hybrids are restricted to the nonresponder haplotype.
Abstract
Immunization of mice with the ABA-GAT conjugate stimulates GAT-specific T helper cells in GAT-responder animals and ABA-specific helpers in nonresponders. U...
Antibody Responses to GAT by (Responder × Nonresponder)F1 Spleen Cells Stimulated by Parental GAT-Macrophages
Antibody Responses to GAT by (Responder × Nonresponder)F1 Spleen Cells Stimulated by Parental GAT-Macrophages
Abstract
The development of IgG PFC responses specific for the random terpolymer of l-glutamic acid60-l-alanine30-L-tyrosine10 (GAT) by virgin and immune (responder ...
Perturbation of GABA Biosynthesis Links Cell Cycle to ControlArabidopsis thalianaLeaf Development
Perturbation of GABA Biosynthesis Links Cell Cycle to ControlArabidopsis thalianaLeaf Development
AbstractTo investigate the molecular mechanism underlying increasing leaf area in γ-Aminobutyric acid (GABA) biosynthetic mutants, the first pair of true leaves of GABA biosyntheti...
Vigabatrin
Vigabatrin
Summary: γ‐Aminobutyric acid (GABA) was first proposed as a putative inhibitory neurotransmitter by Elliot and van Gelder in 1958. Since then, numerous efforts have been made to f...
1737-P: Bulk GABA Secretion from Pancreatic Islets Is Not Co-released with Insulin
1737-P: Bulk GABA Secretion from Pancreatic Islets Is Not Co-released with Insulin
Introduction & Objective: Gamma Aminobutyric Acid (GABA) is a neurotransmitter found in inhibitory neurons but is also synthesized and secreted at high levels in pancreatic isl...
The Effect of Anti-Fatigue of mGluR4, GABA-ARα1 and GABA-BR1 on the Substantia Nigra Pars Reticular During Exercise
The Effect of Anti-Fatigue of mGluR4, GABA-ARα1 and GABA-BR1 on the Substantia Nigra Pars Reticular During Exercise
Objective: The substantia nigra pars reticular (SNR) is the vital nuclei sending out information from basal ganglia and it plays an important part in motor behavior maintenance and...
GABAergic system – physiological role and clinical significance
GABAergic system – physiological role and clinical significance
This work presents a review of the literature using the elibrary.ru, CyberLeninka, PubMed, Scopus and Google Scholar databases with the key terms “Gamma-aminobutyric acid (GABA)”, ...

